Resources from the same session
4844 - EV-103: Initial results of enfortumab vedotin plus pembrolizumab for locally advanced or metastatic urothelial carcinoma.
Presenter: Christopher Hoimes
Session: Proffered Paper 1 – Genitourinary tumours, non-prostate
Resources:
Abstract
Slides
Webcast
4397 - An adaptive, biomarker directed platform study in metastatic urothelial cancer (BISCAY) with durvalumab in combination with targeted therapies
Presenter: Thomas Powles
Session: Proffered Paper 1 – Genitourinary tumours, non-prostate
Resources:
Abstract
Slides
Webcast
811 - ENTRATA: Randomized, double-blind, phase 2 study of telaglenastat (tela; CB-839) + everolimus (E) vs. placebo (pbo) + E in patients (pts) with advanced/metastatic renal cell carcinoma (mRCC)
Presenter: Chung-Han Lee
Session: Proffered Paper 1 – Genitourinary tumours, non-prostate
Resources:
Abstract
Slides
Webcast
1900 - Initial Results From TROPHY-U-01: A Phase 2 Open-Label Study of Sacituzumab Govitecan in Patients (Pts) With Metastatic Urothelial Cancer (mUC) After Failure of Platinum-Based Regimens (PLT) or Immunotherapy
Presenter: Scott Tagawa
Session: Proffered Paper 1 – Genitourinary tumours, non-prostate
Resources:
Abstract
Slides
Webcast
Proffered Paper 1 – Genitourinary tumours, non-prostate - Invited Discussant 901O and 902O
Presenter: Yohann Loriot
Session: Proffered Paper 1 – Genitourinary tumours, non-prostate
Resources:
Slides
Webcast